Core Insights - Tonmya demonstrated significant reduction in fibromyalgia pain compared to placebo in the Phase 3 RESILIENT study, indicating its potential as a well-tolerated, non-opioid analgesic for adults with fibromyalgia [1][2] - The treatment was well tolerated with a discontinuation rate of 19% versus 20.8% for placebo, and minimal effects on weight or blood pressure [1][2] Company Overview - Tonix Pharmaceuticals is a fully integrated biotechnology company with marketed products and a pipeline focused on central nervous system disorders, immunology, immuno-oncology, rare diseases, and infectious diseases [4] - The company received FDA approval for Tonmya on August 15, 2025, marking the first new prescription medicine approval for fibromyalgia in over 15 years [3][4] - Tonix also markets treatments for acute migraine and is developing TNX-102 SL for acute stress reaction and major depressive disorder [4] Clinical Study Details - The RESILIENT study was a 14-week randomized, double-blind, placebo-controlled trial involving 456 participants across 34 U.S. sites, meeting the 2016 American College of Rheumatology criteria for fibromyalgia [2] - Statistically significant reductions in weekly average pain scores were observed at Week 14 (p<0.0001) compared to placebo, along with improvements in sleep quality, fatigue, and other fibromyalgia symptoms [2] Treatment Profile - Tonmya's favorable tolerability profile includes minimal impact on weight and blood pressure, no adverse sexual side effects, and a low rate of adverse event-related discontinuations [2][3] - The most common adverse events were mild oral cavity reactions, which rarely led to study withdrawal [2]

TORONTO, Oct. 27, 2025 (GLOBE NEWSWIRE) -- Carbon Streaming Corporation (Cboe CA: NETZ) (OTCQB: OFSTF) (FSE: M2Q) (“Carbon Streaming” or the “Company”) today announced that it has appointed Jonathan Rubenstein, LLB, as expert consultant to the Company to provide oversight, guidance and strategic direction to the Company for significant litigation. Mr. Rubenstein has decades of experience in the mining sector having transitioned into mining from a successful 18 year career as a lawyer in private practice. As ...

Core Viewpoint - Nurix Therapeutics, Inc. successfully closed an underwritten registered offering of 24,485,799 shares at $10.21 per share, raising gross proceeds of $250 million to fund clinical development and research activities [1][4]. Group 1: Offering Details - The offering included participation from both new and existing investors, highlighting strong support for the company's mission [2]. - J.P. Morgan Securities LLC, Jefferies LLC, and Stifel, Nicolaus & Company acted as joint book-running managers for the offering [3]. - The securities were offered under a shelf registration statement previously filed with the SEC [5]. Group 2: Use of Proceeds - The net proceeds will primarily fund the clinical development of bexobrutideg (NX-5948) for chronic lymphocytic leukemia (CLL) and explore potential autoimmune indications [4]. - Additional funds will support research and development activities to expand the pipeline and cover working capital and general corporate purposes [4]. Group 3: Company Overview - Nurix Therapeutics focuses on targeted protein degradation medicines for oncology and autoimmune diseases, with a pipeline that includes degraders of Bruton's tyrosine kinase (BTK) [8][9]. - The company is advancing multiple potentially first-in-class or best-in-class drug candidates and has collaborations with major pharmaceutical companies like Sanofi and Gilead [8][9].

Core Insights - Electra Battery Materials Corporation has initiated a new program to enhance mineral deposit modeling and feedstock integration at its Iron Creek cobalt-copper project in Idaho, aligning with U.S. efforts to increase domestic critical mineral production and reduce reliance on foreign supply chains [1][2][3] Company Developments - The financing for Electra's North American cobalt refinery is complete, with construction set to resume, allowing the company to leverage its improved balance sheet for growth and to onshore both mineral processing and mining capabilities to meet rising U.S. demand for critical minerals [2][3] - Electra's CEO, Trent Mell, emphasized the strategic importance of Idaho for domestic cobalt production, highlighting the company's plans to diversify its feedstock base by sourcing domestically [3][6] - A new geological research program at Iron Creek, in collaboration with the Centre to Advance the Science of Exploration to Reclamation in Mining (CASERM), aims to refine the geological model and guide future drilling campaigns [4][5][6] Exploration and Resource Development - The new geological program will utilize advanced scanning techniques to better define mineralized zones, which are critical for guiding future drilling efforts [6][9] - Electra holds 10-year exploration permits covering 91 designated drill pad locations across Iron Creek and Ruby, with plans for a drilling restart in spring 2026 based on new findings [9][10] - The company is also collecting bulk samples from Adit 1 for metallurgical testing to refine process design parameters and assess future feedstock integration into its refining operations [10][11] Strategic Vision - Electra's long-term strategy focuses on building a vertically integrated supply chain for critical minerals in North America, with the Idaho mineral assets potentially serving as a domestic feedstock source [11][12] - The company aims to create a continental supply chain that starts with American mining and culminates in refined cobalt sulfate for battery production in North America [12][14]

WARSAW, Ind., Oct. 27, 2025 (GLOBE NEWSWIRE) -- Lakeland Financial Corporation (Nasdaq Global Select/LKFN), parent company of Lake City Bank, today reported net income of $26.4 million for the three months ended September 30, 2025, which represents an increase of $3.1 million, or 13%, compared with net income of $23.3 million for the three months ended September 30, 2024. Diluted earnings per share were $1.03 for the third quarter of 2025 and increased $0.12, or 13%, compared to $0.91 for the third quarter ...

Key Information - The exempt principal trader involved is Investec Bank plc, which is connected to the offeror H2 Equity Partners Ltd regarding Inspecs Group plc [1] - The dealing date is noted as October 23, 2025 [1] Dealings by the Exempt Principal Trader - Purchases of ordinary shares totaled 146,113 units, with the highest price per unit at 47.84 and the lowest price at 43 [3] - Sales of ordinary shares included 31,000 units, with the highest price at 43 and the lowest price at 42.6 [3] Other Information - There are no indemnity or option arrangements related to the relevant securities that may influence dealings [8] - No agreements or understandings regarding voting rights or future acquisition/disposal of relevant securities were reported [9] - The date of disclosure is October 24, 2025 [9]

Core Insights - Nova Minerals Limited has secured a significant funding of US$43.4 million (A$65.5 million) from the U.S. Department of War to support the development of an integrated antimony supply chain in Alaska, highlighting the strategic importance of its Estelle Project [2][16][30] - The company is actively advancing its dual-commodity strategy, focusing on both gold and antimony assets, with ongoing drilling and exploration programs [5][12][19] Financial Position - As of the end of September 2025, the company has access to over A$86.3 million in funding, including A$17.5 million in cash and approximately A$3.3 million in liquid investments [30] - The company raised US$12.1 million (A$18.4 million) in July 2025 through a U.S. offering to fund drilling and exploration programs [30] Estelle Project Developments - The Estelle Project has seen active drilling and surface exploration programs in 2025, with assay results pending [2][12] - The West Susitna Access Road project is progressing, aimed at improving access and reducing mining costs, with construction planned to commence in 2025 [4][5] Antimony Assets - The U.S. Department of War's funding will support the extraction, concentration, and refining of stibnite to produce military-grade antimony trisulfide, enhancing U.S. defense capabilities [16][18] - Nova has commenced resource drilling and stockpiling surface antimony ore, with plans to begin production of antimony trisulfide by 2026 [19][22] Gold Assets - The company is advancing over 20 gold prospects, including four defined multi-million ounce deposits, with ongoing drilling at the RPM North area [8][12] - Recent drilling at the Korbel site targeted a potential higher-grade starter pit, with assay results expected soon [10][12] Strategic Partnerships and Support - Strong backing for the Estelle Project has been demonstrated through engagements with federal, state, and local stakeholders, including visits from U.S. Senator Lisa Murkowski and Alaska Governor Mike Dunleavy [5][19] - The company made a strategic investment of 7.8% in Adelong Gold Limited, enhancing its position in the gold-antimony sector [30]

Core Insights - Brown & Brown, Inc. has been Certified™ by Great Place to Work® for the seventh consecutive year, with its Canadian and U.K. teams receiving certification for the first time [1][2] - The company has also been recognized on the 2025 Fortune Best Workplaces for Women™ List for the fifth year, highlighting its commitment to fostering an inclusive workplace culture [1][2] Employee Experience - 92% of employees reported that Brown & Brown is a Great Place to Work, while 95% felt welcomed upon joining the company [2] - The Great Place To Work Certification is based on real-time employee feedback, emphasizing the importance of employee experience in achieving this recognition [3] Recognition and Awards - Earlier in 2025, Brown & Brown was included in Fortune's Best Workplaces in Financial Services & Insurance list [4] - The company received the 2024-2025 Platinum Level Bell Seal for Workplace Mental Health from Mental Health America for the third consecutive year [4] Company Overview - Brown & Brown, Inc. is a leading insurance brokerage firm with over 700 locations and a workforce of more than 23,000 professionals, providing customized insurance solutions since 1939 [5]

Core Insights - Neumora Therapeutics announced positive preclinical data for NMRA-215, showing class-leading weight loss of up to 19% as a monotherapy and 26% in combination with semaglutide [1][2] - The company plans to initiate a Phase 1 clinical study for NMRA-215 in the first quarter of 2026 [1][2] Company Overview - Neumora Therapeutics is a clinical-stage biopharmaceutical company focused on redefining neuroscience drug development, with a pipeline of seven programs targeting novel mechanisms for various diseases [5] - NMRA-215 is a highly brain-penetrant, oral NLRP3 inhibitor being developed for obesity treatment, with potential implications for Parkinson's disease as well [4][5] Research and Development - NMRA-215 demonstrated significant weight loss in diet-induced obesity mouse studies, indicating its potential as a next-generation oral treatment for obesity [2][4] - The company emphasizes the potential for NMRA-215 to enable incretin-sparing dosing regimens, enhancing its therapeutic profile [2]

Core Insights - Wesdome Gold Mines Ltd. has announced the discovery of a new mineralized zone at the Dubuisson deposit, which is located east of the Kiena Deep deposit in the Kiena Mine Complex, Val-d'Or, Québec [1][2][3] Exploration Results - Drill hole DB-25-068 intersected 4.1 g/t Au over 25.8 metres (core length), indicating significant resource expansion potential [2][3] - The new zone is approximately 100 metres below and lateral to the Dubuisson North Zone, interpreted to be between the Dubuisson North and South zones, suggesting a compelling opportunity for depth expansion [2][3] - The intercept includes higher-grade intervals, such as 6.1 g/t Au over 6.1 metres, highlighting the potential for future bulk-tonnage mineralization at Kiena [3][4] Company Statements - Anthea Bath, President and CEO, emphasized the strong potential for expansion at the Dubuisson deposit, noting the intercept's grade, width, and proximity to existing infrastructure [3] - Jono Lawrence, Senior VP Exploration and Resources, mentioned that the 2025 drilling campaign has completed 41 holes totaling 11,361 metres, indicating the underexplored nature of the Dubuisson deposit [3][4] Technical Details - The Dubuisson deposit currently hosts a probable reserve of 36,400 ounces at 5.8 g/t Au, an indicated resource of 18,000 ounces at 4.6 g/t Au, and an inferred resource of 55,600 ounces at 5.4 g/t Au [4] - The mineralization style at Dubuisson is characterized by quartz-tourmaline veins within diorite intrusive units, distinct from the Kiena Deep deposit [5][6] Future Plans - A follow-up hole is planned before the end of the current barge drilling season, with a larger barge-based drilling program scheduled to commence in summer 2026 [3][4]